Cannabinoid Receptor 2 Protects against Acute Experimental Sepsis in Mice
Open Access
- 1 January 2013
- journal article
- research article
- Published by Hindawi Limited in Mediators of Inflammation
- Vol. 2013, 1-10
- https://doi.org/10.1155/2013/741303
Abstract
The systemic inflammatory response syndrome can be self-limited or can progress to severe sepsis and septic shock. Despite significant advances in the understanding of the molecular and cellular mechanisms of septic shock, it is still one of the most frequent and serious problems confronting clinicians in the treatments. And the effects of cannabinoid receptor 2 (CB2R) on the sepsis still remain undefined. The present study was aimed to explore the role and mechanism of CB2R in acute sepsis model of mice. Here, we found that mice were more vulnerable for lipopolysaccharide- (LPS-) induced death and inflammation after CB2R deletion (CB2R−/−). CB2R agonist, GW405833, could significantly extend the survival rate and decrease serum proinflammatory cytokines in LPS-treated mice. GW405833 dose-dependently inhibits proinflammatory cytokines release in splenocytes and peritoneal macrophages as well as splenocytes proliferation, and these effects were partly abolished in CB2R−/−splenocytes but completely abolished in CB2R−/−peritoneal macrophages. Further studies showed that GW405833 inhibits LPS-induced phosphorylation of ERK1/2 and STAT3 and blocks IκBαdegradation and NF-κB p65 nuclear translocation in macrophages. All data together showed that CB2R provides a protection and is a potential therapeutic target for the sepsis.Keywords
Funding Information
- 501100001809 National Natural Science Foundation of China (30973525, 81172852, 2009CB521901)
This publication has 50 references indexed in Scilit:
- A role for cannabinoid receptors, but not endogenous opioids, in the antinociceptive activity of the CB2-selective agonist, GW405833European Journal of Pharmacology, 2005
- Inhibition of TLR-4/MD-2 signaling by RP105/MD-1Innate Immunity, 2005
- Cannabinoid antagonist AM 281 reduces mortality rate and neurologic dysfunction after cecal ligation and puncture in ratsCritical Care Medicine, 2005
- Pharmacological and pharmacokinetic characterization of the cannabinoid receptor 2 agonist, GW405833, utilizing rodent models of acute and chronic pain, anxiety, ataxia and catalepsyNeuropharmacology, 2005
- Dok-1 and Dok-2 are negative regulators of lipopolysaccharide-induced signalingThe Journal of Experimental Medicine, 2005
- Septic shockThe Lancet, 2005
- Presence and functional regulation of cannabinoid receptors in immune cellsLife Sciences, 1999
- Gi protein modulation induced by a selective inverse agonist for the peripheral cannabinoid receptor CB2: implication for intracellular signalization cross-regulation.1999
- Suppression of Interleukin-2 by the Putative Endogenous Cannabinoid 2-Arachidonyl-Glycerol Is Mediated through Down-regulation of the Nuclear Factor of Activated T CellsMolecular Pharmacology, 1998
- A Combined Assay of Cell Viability and in Vitro Cytotoxicity with a Highly Water-Soluble Tetrazolium Salt, Neutral Red and Crystal Violet.Biological & Pharmaceutical Bulletin, 1996